Core Viewpoint - Teva Pharmaceutical Industries Ltd. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 8:15 A.M. Pacific Time [1] Company Overview - Teva is transforming into a leading innovative biopharmaceutical company, supported by a strong generics business, with over 120 years of commitment to improving health [3] - The company focuses on innovation in neuroscience and immunology, as well as providing complex generic medicines, biosimilars, and pharmacy brands globally [3] - Teva aims to address patients' needs both now and in the future, emphasizing their dedication to better health [3]

Group 1 - Abbott Laboratories is acquiring Exact Sciences for approximately $21 billion, representing a 51% premium over its previous trading price, marking the largest healthcare deal in two years and the largest diagnostic acquisition ever [1] - The acquisition is expected to enhance Abbott's diagnostic business, particularly in colorectal cancer screening, leveraging Exact Sciences' strong product offerings [1] - The deal's approval is anticipated to be smoother under the Trump administration compared to the Biden administration, which has shown a more hostile stance towards mergers [1] Group 2 - Abbott Laboratories develops and sells a variety of healthcare products, including generic medicines, diagnostic systems, nutrition brands, cardiovascular and diabetes care devices, and neuromodulation technologies [2]